Table 3.

Results of base case and worst-case scenario analysis over a time horizon of two, four, six, eight and ten years

Scenario	Treatment	Cost ($)*	QALY	Incremental Cost ($)	Incremental Effectiveness (QALY gained)	ICER ($/QALY)
10-year time horizon
Base-case	Usual care	116,156	6.84	1,662,765	0.45	3,655,352
	Lumacaftor/ivacaftor	1,778,921	7.29
Worst-case	Usual care	116,156	6.84	1,677,901	0.20	8,480,265
	Lumacaftor/ivacaftor	1,794,056	7.04
2-year time horizon
Base-case	Usual care	30,469	2.23	531,606	0.07	7,311,801
	Lumacaftor/ivacaftor	562,075	2.3
Worst-case	Usual care	30,469	2.23	532,262	0.06	9,292,285
	Lumacaftor/ivacaftor	562,731	2.28
4-year time horizon
Base-case	Usual care	51,850	3.56	852,463	0.15	5,835,535
	Lumacaftor/ivacaftor	904,313	3.70
Worst-case	Usual care	51,850	3.56	855,802	0.09	9,554,343
	Lumacaftor/ivacaftor	907,652	3.65
6-year time horizon
Base-case	Usual care	72,361	4.77	1,148,863	0.24	4,869,328
	Lumacaftor/ivacaftor	1,221,224	5.00
Worst-case	Usual care	72,361	4.77	1,155,718	0.12	9,263,760
	Lumacaftor/ivacaftor	1,228,079	4.89
8-year time horizon
Base-case	Usual care	94,274	5.86	1,418,488	0.34	4,173,169
	Lumacaftor/ivacaftor	1,512,761	6.20
Worst-case	Usual care	94,274	5.86	1,429,656	0.16	8,861,944
	Lumacaftor/ivacaftor	1,523,930	6.02

QALY Quality adjusted life year, ICER Incremental-cost effectiveness ratio

^*All costs are expressed in USD-2016